Nicholas Lawrence
@nicholasjlawrence.bsky.social
Chemistry Professor at the Moffitt Cancer Center. Views personal.
Great news!
September 18, 2025 at 9:08 PM
Great news!
Congratulations Andrew!
August 20, 2025 at 5:53 PM
Congratulations Andrew!
Downloaded. Thanks
May 10, 2025 at 12:10 AM
Downloaded. Thanks
ABBV-CLS-484 is a first-in-class, orally bioavailable PTPN2/N1 phosphatase inhibitor, being evaluated as a potential cancer immunotherapy agent. A rare example of a bioavailable active site phosphatase inhibitor. To be added to next year's lecture notes. Hoping for positive results in the clinic!
April 24, 2025 at 7:37 PM
ABBV-CLS-484 is a first-in-class, orally bioavailable PTPN2/N1 phosphatase inhibitor, being evaluated as a potential cancer immunotherapy agent. A rare example of a bioavailable active site phosphatase inhibitor. To be added to next year's lecture notes. Hoping for positive results in the clinic!
A great event yesterday morning. Really looking forward to moving our lab to the Innovation Center next year!
April 23, 2025 at 1:44 PM
A great event yesterday morning. Really looking forward to moving our lab to the Innovation Center next year!
This was really good!
April 12, 2025 at 1:22 AM
This was really good!
Bittersweet. But congratulations to your students and the whole cohort. Good luck to them all.
April 12, 2025 at 1:21 AM
Bittersweet. But congratulations to your students and the whole cohort. Good luck to them all.
Good luck Stuart. Let them know there's plenty of opportunities for internships in all things drug discovery!
March 4, 2025 at 9:40 PM
Good luck Stuart. Let them know there's plenty of opportunities for internships in all things drug discovery!
Well done Julian. Congratulations! All the best for retirement.
February 20, 2025 at 3:49 PM
Well done Julian. Congratulations! All the best for retirement.